Wilms Tumor Panel
Use
This test is intended for individuals with clinically relevant features suggestive of hereditary Wilms tumor, including those with a clinical or suspected diagnosis. This includes individuals diagnosed with early-onset Wilms tumor before 2 years of age, those with bilateral or multicentric Wilms tumor, or those having a family history of Wilms tumor. It is also applicable to individuals with a personal or family history that aligns with a syndromic Wilms tumor presentation.
Special Instructions
The test uses the PGselect platform, known for incorporating NGS with CNV analysis. Prenatal and STAT testing options are available, with a surcharge applied to STAT requests. Institutional pricing can be accessed by signing in. Detailed information regarding targeted family testing and additional options for testing can be explored upon receiving the test report.
Limitations
The test is not cleared or approved by the US Food and Drug Administration, which might affect certain regulatory impressions. The performance characteristics have been validated by the laboratory under CAP and CLIA regulations but are subject to the quality of clinical information provided. The test is limited to the genes included in the panel and might not detect all potential mutations associated with Wilms tumor.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided